Clinical Trial Update: Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating subcutaneous immunotherapy gpASIT+ for grass pollen-induced allergic rhinoconjunctivitis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Grass Pollen-induced Allergic Rhinoconjunctivitis
• Hay Fever

Drugs mentioned

• gpASIT+™ (gpASIT+™)

Snippet

Sponsor: BioTech Tools S.A. | Conditions: Hay Fever | Phase 3 | Status: COMPLETED